Fig. S5 from A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in <i>KRAS</i>-Mutant Colon Cancer Cells

figure

posted on 2023-04-03, 15:03 authored by Akira Inoue, Tsunekazu Mizushima, Xin Wu, Daisuke Okuzaki, Nanami Kambara, Sho Ishikawa, Jiaqi Wang, Yamin Qian, Haruka Hirose, Yuhki Yokoyama, Ryo Ikeshima, Masayuki Hiraki, Norikatsu Miyoshi, Hidekazu Takahashi, Naotsugu Haraguchi, Taishi Hata, Chu Matsuda, Yuichiro Doki, Masaki Mori, Hirofumi Yamamoto

<p>Supplementary Figure S5. Evaluation of the toxicity of super carbonate apatite-MIRTX conjugate and effect of systemic administration of formulated MIRTX on tumor growth in vivo. The DLD1 xenograft mouse models received intravenous administrations of MIRTX or control-miR using super carbonate apatite (sCA) as a vehicle on days 0, 2, 4, 7, 9, 12, 14, and 16 via a tail vein injection. Each injection contained 40 μg of formulated oligo with a 40% conjugation rate. Tumors were resected on day 18. (A) Blood chemistry tests were performed on day 18 for the parent, treated with sCA-control-miR, and treated with sCA-MIRTX. NS: not significant. (B) Hematoxylin and eosin-stained section of each organ tissue (brain, heart, lung, liver, spleen, kidney, colon) revealed no particular histological damage in formulated sCA-MIRTX-treated mice. (C) Tumor weights were evaluated for the parent (n = 8), treated with sCA-control-miR (n = 8), and treated with sCA-MIRTX (n = 8). Injection of sCA-MIRTX significantly decreased tumor weights. (D) Another cohort using HT29. All data represent mean {plus minus} SD. *p < 0.01.</p>

Funding

KAKENHI

History

Related Materials

1.
DOI - Is supplement to A miR-29b Byproduct Sequence Exhibits Potent Tumor-Suppressive Activities via Inhibition of NF-κB Signaling in KRAS-Mutant Colon Cancer Cells

ARTICLE ABSTRACT

We previously demonstrated that miR-29b-3p is a hopeful miRNA-based therapy against colorectal cancer. In this study, we aimed to clarify a value of miR-29b-1-5p as a next-generation treatment, especially for KRAS-mutant colorectal cancer. RT-PCR assay showed that the expression of miR-29b-3p was high, and its partner strand, miR-29b-1-5p, level was only negligible in clinical colorectal cancer samples. Mimic-miR-29b-1-5p significantly inhibited proliferation of KRAS-mutant colorectal cancer cell lines DLD1 and SW480 and KRAS wild-type HT29 cells. Proliferative activity was further examined by either miR-29b-1-5p strand or its opposite complementary sequence because miR-29b-1-5p is a passenger miRNA and may have no physiologic function. We found that completely opposite complementary strand to miR-29b-1-5p, but not miR-29b-1-5p, possessed a potent antitumor effect and named this byproduct miRNA sequence “MIRTX.” MIRTX directly targeted the 3′-UTR of CXCR2 and PIK3R1 mRNA and suppressed the NF-κB signaling pathway in KRAS-mutated colorectal cancer cells. MIRTX induced apoptosis in DLD1 with downregulation of antiapoptotic BCL2, BCL-xL, and MCL1 and upregulation of cleaved caspase-3 and cleaved PARP. In mouse xenograft models, systemic administration of MIRTX using a super carbonate apatite as a delivery vehicle significantly inhibited tumor growth of DLD1 and HT29 cells without any particular toxicities. In conclusion, these findings indicate that inhibition of NF-κB signaling by this novel miRNA-based therapeutic could be a promising treatment against refractory KRAS-mutant colorectal cancer and KRAS wild-type colorectal cancer. Mol Cancer Ther; 17(5); 977–87. ©2018 AACR.